Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cytokinetics, Inc.    CYTK   US23282W1009


SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

08/19/2011 | 08:40am US/Eastern
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

Recommend :
React to this article
Latest news on CYTOKINETICS, INC.
2d ago CYTOKINETICS : Results of Operations and Financial Condition, Financial Statemen..
2d ago CYTOKINETICS, INC. : Incorporated Reports Second Quarter 2014 Financial Results
2d ago CYTOKINETICS : Reports Second Quarter 2014 Financial Results
07/16 CYTOKINETICS : to Announce Second Quarter Results on July 30, 2014
07/15 CYTOKINETICS : Assigned Patent
07/10 CYTOKINETICS : Other Events (form 8-K)
07/10 CYTOKINETICS : Announced Additional Results Relating to Tirasemtiv from Pre-Spec..
07/03 CYTOKINETICS : Announces Additional Data from BENEFIT-ALS to be Presented at the..
06/30 CYTOKINETICS : Assigned Patent
06/13 CYTOKINETICS : Announces Data Relating to Tirasemtiv Presented at the 2014 Annua..
Duration : Period :
Cytokinetics, Inc. Technical Analysis Chart | CYTK | US23282W1009 | 4-Traders
Income Statement Evolution
Cytokinetics, Inc. : Income Statement Evolution
More Financials
Dynamic quotes